发布时间：2026-01-05 行业投资评级 证券研究报告：医药生物|行业周报 强于大市 |维持 行业基本情况 | 收盘点位 | | 8084.61 | | --- | --- | --- | | 52 | 周最高 | 9323.49 | | 52 | 周最低 | 6764.34 | 行业相对指数表现 2025-01 2025-03 2025-05 2025-08 2025-10 2025-12 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:龙永茂 SAC 登记编号:S1340523110002 Email:longyongmao@cnpsec.com 近期研究报告 《国内创新药研发景气回暖，关注非临 床安评行业投资机会》 - 2025.12.29 医药生物行业报告 （2025.12.29-2025.12.31） 零售药店行业加速出清，行业集中度提升龙头受益 l 本周主题 零售药店行业在 20 ...

Core Viewpoint - The company currently does not have a dedicated beauty division but has established a non-pharmaceutical division that includes beauty products [1] Group 1 - An investor inquired about the possibility of setting up a dedicated beauty division for online marketing and live streaming [1] - The company responded that its organizational structure does not currently include a beauty division [1] - The non-pharmaceutical division covers the beauty business [1]

CVS 健康首席财务官布莱恩・纽曼周二表示："2025 年，我们各业务板块均收获了可观的发展势头，顺 利收官；2026 年，我们预计将迎来又一个盈利强劲增长的年份。" 来源：环球市场播报 美国零售药店巨头 CVS 健康于周二发布业绩指引，预计 2026 年利润将超过华尔街预期及公司本年度的 盈利目标，这一信号表明这家医疗健康集团的转型计划正稳步推进。 该公司曾在 10 月份第三次上调 2025 年利润预期，并同时预计 2026 年将实现两位数的盈利增长。 据伦敦证券交易所集团（LSEG）汇总的数据，CVS 健康预计 2026 年调整后每股收益将在 7.00 至 7.20 美元区间，而分析师平均预期值为 7.16 美元。 不过，该公司预计 2026 年总营收至少为 4000 亿美元，低于分析师 4192.6 亿美元的平均预期。 此外，CVS 健康还将 2025 年调整后每股收益预期从此前的 6.55 至 6.65 美元，上调至 6.60 至 6.70 美 元。 ...

Group 1 - The upcoming removal of the tax exemption for contraceptives in 2026 will significantly increase costs for manufacturers, potentially raising prices by over 15% due to a 13% VAT on production costs [1] - The change in tax policy reflects a shift in China's population strategy, moving from controlling birth rates to encouraging them, as evidenced by the introduction of a tax exemption for marriage introduction services [2] - The financial impact on companies with annual sales exceeding 100 million yuan could be substantial, leading to a potential re-evaluation of financial statements due to the sudden increase in tax burdens [1] Group 2 - The tax reform is part of a broader demographic strategy, linking the price fluctuations of contraceptives to macroeconomic policies, thus involving consumers in a larger societal change [2] - The historical context of the tax exemption for contraceptives illustrates the evolution of China's population policies, transitioning from quantity control to quality enhancement [2] - Companies may need to adjust their supply chain costs in response to consumer behavior shifting towards cheaper brands, which could lead to market segmentation [1]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The retail pharmacy sector is expected to benefit from the recent surge in flu cases, with a significant increase in demand for antiviral medications and symptomatic treatments [5][15] - The retail pharmacy industry is anticipated to undergo accelerated consolidation, with smaller pharmacies exiting the market, leading to increased customer traffic for leading players [6][34] - The implementation of drug traceability codes is expected to enhance industry compliance and further increase market concentration [6][18] Summary by Sections Industry Overview - The closing index for the industry is 8430.03, with a 52-week high of 9323.49 and a low of 6764.34 [2] Recent Market Performance - The A-share pharmaceutical sector rose by 2.67% from November 24 to November 28, 2025, outperforming the CSI 300 index by 1.03 percentage points [19][35] - The Hang Seng Healthcare Index increased by 3.64%, outperforming the Hang Seng Index by 1.1 percentage points [35][36] Industry Insights and Investment Recommendations 1. **Innovative Drugs**: The long-term trend for innovative drugs is positive, with China's capabilities in global competition strengthening [9][21] - Recommended stocks include Innovent Biologics, Kintor Pharmaceutical, and others [10][22] 2. **Medical Devices**: The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3 [10][26] - Recommended stocks include Mindray, Aohua Endoscopy, and others [27][28] 3. **Traditional Chinese Medicine**: The sector is under pressure but is expected to benefit from basic drug policies and innovation [31][32] - Recommended stocks include Zhaoke Ophthalmology, Fangsheng Pharmaceutical, and others [31][32] 4. **Retail Pharmacy**: The retail pharmacy sector is expected to see increased concentration, with leading pharmacies benefiting from enhanced service capabilities and supply chain management [6][34] - Recommended stocks include Yifeng Pharmacy and Dazhong Pharmacy [7][34]

Core Viewpoint - The pharmaceutical sector has shown a volatile upward trend since early 2025, with a brief correction highlighting its cost-effectiveness, despite current valuations being at historical medians since 2010, indicating room for market capitalization growth [1] Group 1: Innovative Drug Industry Chain - Emphasis on innovation and the importance of high-quality domestic clinical data to catalyze opportunities for profit recovery in the industry [2] - Domestic assets are gaining global recognition, with strong demand for new product iterations and favorable conditions for domestic new drugs to enter international markets [2] - The dual-antibody market (PD-(L)1/VEGF) is experiencing increasing market heat and transaction value, with potential for synergistic effects alongside ADC mechanisms [2] Group 2: New Therapeutic Approaches - High demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to maintain rapid growth, with a recovery in outsourcing demand anticipated during the overseas interest rate decline [3] - The domestic market is poised for a recovery in demand and primary market conditions, with a potential for rapid profit recovery as supply-side capacity reduction slows [3] Group 3: Non-Pharmaceutical Sector - Medical devices are showing signs of a turning point, with growth stabilizing for certain companies and a recovery in bidding processes expected to impact 2026 performance positively [4] - The traditional Chinese medicine sector is likely to see continued adjustments in essential drug catalogs, with opportunities arising from price declines in raw materials [4] - Retail pharmacies are undergoing accelerated consolidation, with leading pharmacies optimizing store structures to alleviate profit pressures, leading to expected profit margin improvements in 2026 [4]

Investment Strategy Overview - The core investment strategy for the pharmaceutical sector in 2026 emphasizes innovation and the recovery of profitability within the industry, as the sector has shown signs of stabilization after a period of volatility [4][30]. Innovative Drug Industry Chain - The domestic innovative drug sector is gaining global recognition, with a significant increase in the attention from multinational corporations (MNCs) towards domestic assets. The demand for new products is strong, driven by the approaching patent cliffs for MNCs and favorable policies for domestic drugs entering international markets [5][44]. - The market for PD-(L)1/VEGF bispecific antibodies is experiencing heightened interest, with complementary mechanisms to antibody-drug conjugates (ADCs) expected to drive synergy and growth [5][51]. - The demand for new therapeutic modalities such as peptides, ADCs, small nucleic acids, and cell and gene therapies (CGT) is projected to maintain high growth rates, supported by a recovering outsourcing demand during the overseas interest rate decline [6][43]. Non-Pharmaceutical Sector - The medical device sector is showing signs of recovery, with some companies reporting improved performance in Q3 2025. The bidding for medical equipment is expected to continue recovering, leading to better performance in 2026 [6][7]. - The traditional Chinese medicine sector is anticipated to benefit from ongoing adjustments to the essential drug list, with opportunities for price increases and improved profit margins for leading companies [6][7]. Retail Pharmacy Sector - The retail pharmacy industry is undergoing accelerated consolidation, with leading pharmacies optimizing their store structures to alleviate profit pressures. This is expected to result in a noticeable improvement in profit margins in 2026 [7]. Market Performance and Valuation - The pharmaceutical sector has shown a rebound since early 2025, with a notable increase in the market index, outperforming the broader market indices. As of November 21, 2025, the CITIC Pharmaceutical Index had risen by 14.68% [15][30]. - The valuation of the pharmaceutical sector is at a historical median since 2010, with a price-to-earnings (PE) ratio of 48.38X, indicating a high premium compared to the broader market [17][30]. - The scale of pharmaceutical funds reached a record high of 226 billion yuan by Q3 2025, although the market capitalization of pharmaceutical stocks remains below historical peaks, suggesting potential for growth [20][24]. Financial Performance - The pharmaceutical sector's revenue for the first three quarters of 2025 was 185.46 billion yuan, reflecting a year-on-year decline of 1.34%. However, Q3 2025 showed a revenue increase of 1.18% compared to the previous quarter, indicating signs of recovery [30][31]. - The net profit attributable to shareholders for the pharmaceutical sector in the first three quarters of 2025 was 14.06 billion yuan, down 1.69% year-on-year, but with a positive growth of 3.61% in Q3 2025 compared to the previous quarter [30][31].

Core Viewpoint - The company, Lao Bai Xing, has experienced a decline in stock price and financial performance, with significant changes in shareholder structure and trading activity [1][2]. Group 1: Stock Performance - On November 20, Lao Bai Xing's stock price fell by 1.51%, with a trading volume of 197 million yuan [1]. - The financing buy-in amount for the day was 17.15 million yuan, while the financing repayment was 16.26 million yuan, resulting in a net financing buy of 890,200 yuan [1]. - As of November 20, the total financing and securities lending balance was 516 million yuan, with the financing balance at 515 million yuan, accounting for 4.15% of the circulating market value, which is below the 40th percentile level over the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, Lao Bai Xing reported a revenue of 16.07 billion yuan, a year-on-year decrease of 1.00%, and a net profit attributable to shareholders of 529 million yuan, down 16.11% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 2.175 billion yuan in dividends, with 1.097 billion yuan distributed over the past three years [2]. Group 3: Shareholder Structure - As of October 31, the number of shareholders for Lao Bai Xing increased to 63,700, up by 1.94%, while the average circulating shares per person decreased by 1.90% to 11,921 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 7.76 million shares, a decrease of 7.32 million shares from the previous period [2].

Group 1: Non-automobile Insurance Industry - The implementation of "reporting and operation integration" for non-automobile insurance aims to guide insurance companies towards reasonable pricing and healthy competition, addressing long-standing issues of irrational competition and high costs [5][6][7] - The new regulations require a phased approach to re-filing, with specific deadlines for different non-automobile insurance products, ensuring a smooth transition to the new policy [6] - The regulations set differentiated rate caps for large and small companies, with larger firms facing stricter constraints, which reflects a commitment to rigorous regulatory oversight [7][8] Group 2: Household Appliances Industry - The domestic sales of robotic vacuum cleaners show a significant impact from the high base last year, with a notable decline in sales volume and revenue in October, prompting some companies to offer short-term discounts [11][12] - Innovative products like the active water washing technology are leading the market, with companies like Ecovacs gaining a competitive edge through early adoption and product upgrades [12][13] - The Southeast Asian market is emerging as a new growth area for robotic vacuum cleaners, with significant sales growth reported, particularly in Vietnam [14][15] Group 3: Yifeng Pharmacy (603939) - Yifeng Pharmacy reported steady profit growth with a revenue of 17.286 billion yuan in the first three quarters of 2025, reflecting a year-on-year increase of 0.39%, and a net profit of 1.225 billion yuan, up 10.27% [17][18] - The company is focusing on high-quality development by slowing down store expansion and optimizing its operational structure, which has led to improved same-store sales [19] - The new retail business continues to grow rapidly, with significant contributions from B2C sales, indicating successful adjustments in online strategies [18][19]

Core Viewpoint - Donghai Securities report indicates that Yifeng Pharmacy achieved a net profit attributable to shareholders of 1.225 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 10.27% [1] Financial Performance - In Q3 alone, the company reported a net profit attributable to shareholders of 345 million yuan, which is a year-on-year increase of 10.14% but a quarter-on-quarter decrease of 19.98% [1] Operational Efficiency - The company has demonstrated robust profit growth through cost reduction, efficiency enhancement, and optimization of its operational structure, showcasing its excellent management capabilities and operational resilience [1] Business Strategy - The new retail business continues to grow significantly, and the initial results of the non-pharmaceutical innovation strategy are becoming evident [1] - The company plans to launch a transformation of non-pharmaceutical innovative stores in 2025, with nationwide promotion expected in 2026, which is anticipated to open new growth opportunities [1] Market Position - Yifeng Pharmacy is recognized as a leading retail pharmacy with stable operations and unique refined management capabilities, while its diversified business approach is expected to provide long-term development potential [1] Investment Rating - The report maintains a "Buy" rating for the company [1]